Metal-Phenolic Nanocloaks on Cancer Cells Potentiate STING Pathway Activation for Synergistic Cancer Immunotherapy

Area of Science:

• Biotechnology
• Immunology
• Materials Science

Background:

• Autologous tumor cell vaccines show promise for personalized cancer therapy due to natural neoantigens.
• Current production methods often lead to antigen loss, reducing immune activation and clinical utility.

Purpose of the Study:

• To develop a novel whole-cell cancer vaccine strategy to overcome limitations of autologous tumor cell vaccines.
• To engineer a nanobiohybrid system for enhanced cancer immunotherapy.

Main Methods:

• Cancer cells were cloaked with lipopolysaccharide-decorated manganese(II)-phenolic networks (MnTA nanocloaks).
• Polyphenols coordinated with Mn2+ to form nanocloaks, encapsulating tumor neoantigens.
• Lipopolysaccharide decoration facilitated dendritic cell internalization and Mn2+ release, activating the stimulator of the interferon genes (STING) pathway.

Main Results:

• The MnTA nanocloaks effectively encapsulated tumor neoantigens on cancer cells.
• Internalization by dendritic cells led to Mn2+ release and STING pathway activation.
• Combining nanocloaked cancer cells with anti-programmed cell death ligand 1 (anti-PD-L1) antibodies resulted in highly effective tumor suppression.

Conclusions:

• A universal and simple strategy was developed to engineer a cell-based nanobiohybrid system.
• This approach enhances cancer immunotherapy by improving immune activation and efficacy.
• The nanocloaked cancer cell vaccine shows significant potential for synergistic cancer treatment.